Dr. David Weiner directs a translational research laboratory at The Wistar Institute in the area of Molecular Immunology. His group is one of the pioneering research teams in establishing the field of DNA vaccines and immunotherapies. Important reports from his lab include the first DNA vaccine studied for HIV as well as for cancer immunotherapy, the early development of DNA encoded genetic adjuvants including the particularly relevant IL-12, advances in gene optimization, and advances in electroporation (EP) technologies resulting in improved gene delivery among others. His group worked with collaborators to become the first to move DNA technology into human study. His laboratory’s work helped revitalize the field through advancement of new synthetic DNA design and modification of EP delivery approaches resulting in potent immune induction as well as the first successful Phase IIb DNA efficacy study (for HPV immunotherapy) in humans. Dr. Weiner is the recipient of numerous honors including election as a fellow to both the American Association for the Advancement of Science in 2011 and the International Society for Vaccines in 2012. He is the recipient of the NIH Director’s Transformative Research Award and received the Vaccine Industry Excellence Award for Best Academic Research Team in 2015 at the World Vaccine Congress. Weiner was honored with the prestigious Hilleman Lectureship in 2015 at the Children’s Hospital of Philadelphia Grand Rounds session and received a Stone Family Award from Abramson Cancer Center for his groundbreaking work on DNA vaccines for cancer immunotherapy. In 2019, Dr. Weiner was honored with the Scientific Achievement Award from Life Sciences PA (LSPA). Dr. Weiner returned to Wistar in 2016 from his position at The University of Pennsylvania School of Medicine as professor of Pathology and Laboratory Medicine. From 1990 to 1993, Weiner held a joint position as assistant professor of Pathology and Laboratory Medicine at The Wistar Institute and the University of Pennsylvania School of Medicine. Dr. Weiner is a co-founder of Inovio Pharmaceuticals and is a member of the Board of Directors. Dr. Weiner graduated with a B.S. in biology from SUNY at Stony Brook, N.Y., a M.S. in biology from the University of Cincinnati and a Ph.D. in developmental biology from the University of Cincinnati College of Medicine.

Dr. Bin Wang is the Co-founder, Chairman of Advaccine Biotechnology Co LTD. He is also holding a distinguished professor position at the Fudan University School of Basic Medical Sciences and serves as the chairman for the Nucleic Acid Vaccines branch of the Chinese Vaccine Society. His research area is focused on the effects of therapeutic vaccination to activate T cells and the mechanism of immune regulations. He has developed novel adjuvants and recombinant vaccines, novel DNA vaccine delivery, and led to several developed vaccines being tested in human clinical trials. He received his Ph.D. from the Cincinnati Children's Hospital at the University of Cincinnati School of Medicine in 1990. He completed his postdoc training in virology and immunology at the Wistar Institute in 1992 in Philadelphia. He became an instructor and assistant professor at the University of Pennsylvania Medical School from 1993 to 1998. He was a professor and served as the Chairman of the Department of Microbiology and Immunology for six years at the College of Biological Sciences, China Agricultural University before he joined Fudan University. He was one of the very early DNA vaccine technology inventors in the 90’s and performed the first-in-human DNA vaccine trials in 1994-1996. He has been involved in several clinical trials of therapeutic vaccines against chronic HBV infections in recent years and invented a novel prophylactic RSV vaccine currently under clinical phase II testing. He has published over 160 peer-review articles and awarded 35 US and 30 Chinese patents. He serves as an editorial board member for several international journals and executive member in several professional societies.

Dal-Hee Min is currently co-founder & CTO of Lemonex and Professor at Seoul National University. She received her Ph.D in Chemistry from University of Chicago. After post-doctoral research at MIT, she started her academic carrier at KAIST (Korea) as an Assistant Professor in 2007 and moved to Seoul National University in 2011. Her research focuses on drug delivery systems with collective understanding on nano-surface chemistry and diverse biomedical applications of nanomaterials including mRNA vaccines and gene therapies. She received various prestigious awards including ‘KCS-Wiley Young Chemist Award’, ‘Korea L’Oreal UNESCO Fellowship Award for Women in Science’ and ‘Order of Science and Technological Merit (Do-Yak Medal)’ from Korea Government. She is actively involved in many global activities. For highlighted activities, she gave two invited talks at World Economic Forum in 2018 where she introduced DegradaBALL technology-‘Miniaturizing Biotechnology’ in sessions ‘Bio-Inspired Drug Delivery’ and ‘Harnessing Nature for Technology ‘. She also gave talks about drug delivery platform technology at mRNA health conference, PODD, JP Morgan and BIO USA. Focus Area: mRNA vaccine / gene therapy / Nanobiotechnology / Nanomedicine/ Drug Delivery / Immunotherapy

Heinrich Haas， Department of Biopharmaceutics and Pharmaceutical Technology Johannes Gutenberg-Universität, Mainz Mainz, Germany. Ph.D. in the group of Prof. Dr. Helmuth Möhwald at Johannes-Gutenberg Universität Mainz. Researched lipid membranes and organized bio-molecular systems. In pharmaceutical industry (Munich Biotech, Medigene, BioNTech) developed different types of nanoparticle products to clinical stage. Focus on advanced approaches for nanoparticle development and control.

Guanghui Ma is a professor of the State Key Laboratory of Biochemical Engineering (SKLBCE), Institute of Process Engineering (IPE). She is an academician of CAS in China and AIMBE fellow. She is serving as Director of the State Key Laboratory of Biochemical Engineering. She received Bachelor degree from Gunma University, Master and PhD degrees from Tokyo Institute of Technology, respectively. She joined SKLBCE as a professor in 2001 and was promoted to the director in 2012. Her research interests focus on the preparation of uniform microspheres and microcapsules and their applications in biochemical engineering and biomedicine engineering, such as biochemical separation media, drug carriers, vaccine adjuvants (vaccine delivery systems), microcarriers for cell culture, and enzyme immobilization carriers. She has published over 500 papers, including Nat. Mater., Nat. Nanotechnol. Nat. Biomed. Eng., Nat. Commun., Sci. Adv., JACS, Adv. Mater., etc. She has more than 90 patents authorized, the technology and products have been commercialized in companies, and have been used in more than 500 affiliations in the world. She has received the State National Invention Award (2nd Class; 2009), the Beijing Science and Technology Award (1st Class; 2005), the Basic Research Achievement Award (1st Class prise of Science and Technology Award; 2020) of the Chemical Industry and Engineering Society of China, and Natural Science Award (1st Class; 2020) of the Chinese Society of Particuology.

South Ural University, New York, NY. Master of Business Administration, 2002. Institute of Virology, Moscow, Russia. PhD (in Virology), 1988. Moscow Pedagogical University, Moscow, Russia. Master of Science, 1980. IVANOVSKY INSTITUTE OF VIROLOGY, Moscow, Russia Research Scientist (1980-1989), Laboratory Supervisor (1989-1990) NEW YORK UNIVERSITY MEDICAL CENTER, New York, New York Associate Research Scientist (1990-1994) SPECIALITY LABORATORIES, Santa Monica, California Research Scientist (1996-1998) FOCUS TECHNOLOGIES (former MRL), Cypress, California Senior Scientist (1998-2001) UNITED STATES GOVERNMENT (Center For Disease Control and Prevention), Project Manager - Consultant (2001-2003) PATHWAY DIAGNOSTICS, Malibu, California Director, Assay Development (2003-2007) INDEPENDANT CONSULTANT, Santa Monica, California (2007 - 2009) INTERNATIONAL VACCINE INSTITUTE (IVI), Seoul, Korea Laboratory Coordinator (2009-2011) FGUP SPbNIIVS FMBA RUSSIA, S-Petersburg, Russian Federation Adviser to Director of Institute (2013 - 2020) Scientific Director (2020 – present) Analytical research and scientific management of a new product development, intellectual property conceptualization, international collaboration.

Mr. Chunlin Xin is the Vice President of CanSino Biologics, where he currently oversees External R&D and scientific affairs. With over 20 years of experience in the biotech industry, Mr. Xin previously served as the Oncology Biomarker technical leader at the Novartis BioMedical Research Institute in the United States and China. He has also worked as a technical officer at the National Research Institute of Canada and as a senior scientist at the Merck Canada Research Institute. Mr. Xin graduated from the Virology Institute at the CDC China and spent five years as a visiting scholar at the University of North Carolina in the United States. In 2017, he joined CanSino as Senior Director of R&D, where he was responsible for designing and developing new vaccines and exploring and establishing new technology platforms. Most recently, Mr. Xin has played a lead role in assisting many developing countries in establishing COVID-19 vaccine manufacturing facilities through tech transfer.

Jompong is an engineer who graduated from Chulalongkorn University. He co-founded the Baiya Phytopharm in 2018 and currently serves as its Chief Operating Officer. He has a vision to promote pharmaceutical endeavors and create health security in Thailand, and he oversees the businessmanagement and operations of Baiya. He also works closely with the research team, led by Dr. Waranyoo Poolcharoen, to scale-up production from the lab scale to a larger scale. He has designed a production facility for plant-produced vaccines and biologics, which can produce up to 60 million doses of COVID-19 vaccine per year. His leadership and dedication to his work were evident in the construction of the facility. He oversaw the facility's construction and ensured that it was up and running within eight months. His hard work and commitment paid off, as the facility became the first cGMP plant-produced vaccines and biologics facility for humans in Asia. Jompong's success in his work has been driven by his passion and vision for creating health security in Thailand. He continues to work towards this goal, using his engineering skills and business acumen to make a difference in the world.

Arina Privalova is responsible for Strategy and Business Development at Nanolek, a Russian pharmaceutical company founded in 2011. The company specializes in the prevention and treatment of socially significant diseases and was recognized as a backbone enterprise of the Russian economy in 2020. In 2021, Nanolek was listed as one of the "50 Fastest Growing Companies in Russia." With over four years of experience at Nanolek and a background in consulting and market research in the pharmaceutical industry for over nine years, Arina's main responsibility is to ensure the continuous extension of the company's pipeline by recruiting new products via in-licensing, M&A, and commercialization deals. At VIF 2023, Arina will present an overview of the Russian vaccine market and the cooperation opportunities available with Nanolek.

Shaowei Li Ph.D. Professor of Biochemistry and Structural Vaccinology, Xiamen University Shaowei Li is a tenured Professor of Biochemistry and Structural Vaccinology in the School of Life Sciences with a joint appointment in the School of Public Health, Xiamen University, China. He is the vaccine group leader in the National Institute of Diagnostics and Vaccine Development in infectious diseases (NIDVD), one of the academic leaders in the State Key Laboratory of Molecular Vaccinology and Diagnostics, deputy director in Fujian provincial Xiang An biomedicine laboratory. Dr. Li has inter-disciplinary research interests focusing on structural vaccinology, resulting in more than 120 peer-reviewed papers. He also has translational experience in vaccine development against infectious diseases—such as Hepatitis E vaccine and HPV vaccine, especially in aspects of immunogen design, process development and antigen characterization. Dr. Li has won two of China’s National Science and Technology Awards and been listed in the Top 20 translational researchers of 2016, ranked by Nature Biotechnology. He has served on the Product Development for Vaccines Advisory Committee (PDVAC), World Health Organization (WHO) since 2022.

Dexiang Chen, Doctor of Immunology, Mississippi State University, has been engaged in the development of vaccines and vaccine adjuvants in Pfizer, Novartis and PATH scientific and technological organizations for more than 30 years, and has presided over a number of major international public health special projects funded by international organizations, foundations and national governments. Among the more than 20 infectious disease vaccine development projects presided over and participated in, many products have been listed globally. Dr. Chen Dexiang has published more than 60 vaccine-related academic papers in world-class academic journals such as Science and Nature Medicine.

Dan Shores is a Partner at Rothwell Figg and a founder of its Boston, Massachusetts office. He has an extensive background in IP law in the biotech space and has been practicing in that space during the entirely of his 17-year career including in matters relating to small molecules, biosimilars, mRNA, LNP, and oligonucleotide technologies. Dan is passionate about helping his clients build robust patent portfolios, litigate matters (both as plaintiffs and defendants in the U.S. District Courts and in IPR and other post-grant proceedings), protect trade secrets, negotiate strategic collaborations, conduct due diligence and landscape investigations, and prepare for success in funding rounds and exits. Dan is a problem-solver who excels at deciphering key translational aspects of a broad array of technologies to maximize leverage in the context of clients’ desired implementation of such technologies whether as participants in dynamic markets or as first movers. Dan is a registered patent attorney licensed to practice before the U.S. Patent and Trademark Office. He is a member of the bars of the Supreme Court of the United States, United States Court of Appeals for the Federal Circuit, and United States District Court for the District of Massachusetts.

Dr. Liu Yuanqing graduated from Shanghai Medical College of Fudan University and was a surgeon at Shanghai Zhongshan Hospital. He completed his PhD in Vrije Universiteit Brussel in Belgium and was one of the pioneers on myeloid-derived suppressors in tumors. He was previously a senior research lead at Sanofi Pasteur French headquarter, where he contributed to various vaccine projects, including cancer vaccines, vaccines against infectious diseases, pediatric vaccines, adjuvants, etc. Dr. Liu is an industry veteran with extensive experience in the development of innovative vaccines for international market. He was a member of the EU Innovative Medicine Initiative. Since 2021, he has been the Chief Scientific Officer of Immorna Biotechnology. He is based in Shanghai where Immorna has established a high-standard R&D site aiming to accelerate the development of mRNA vaccines and drugs in China.

Dr Alain Bouckenooghe is currently the Chief Scientific Officer at Hilleman Laboratories where he is leading the R&D department of this biotech company. He has been working in the pharmaceutical industry over 20 years, mostly in vaccine R&D but also in regulatory and medical affairs. Alain obtained his Medical Degree at the Catholic University of Leuven, Belgium. Upon graduation as MD he worked for several years in a rural assignment as a District Medical Officer under the Ministry of Health of Zambia. Subsequently, he completed his residency in Internal Medicine at the University of Texas, Houston. He has a Master of Public Health degree from the UT School of Public Health, Houston TX, and completed a Fellowship in Adult Infectious Diseases at Baylor College of Medicine, Houston TX. Alain held several academic positions during this time in the Department of Medicine at Baylor College. After initial industry experience with MSD and GlaxoSmithKline Biologicals, he joined Sanofi Pasteur in December 2006 to 2018, covering various responsibilities over time, including Regional Head of Clinical R&D Asia Pacific, Regional Head Medical Affairs, and R&D Partnership lead in Asia. Alain joined MSD in 2018 as Associate VP leading the respiratory franchise in Global Clinical Development. Alain feels very fortunate and honoured to be part of the Hilleman Laboratories team aiming to provide effective and affordable solutions for Global Health problems especially those impacting lower and middle income countries.

Lianpan Dai, PhD, Principal Investigator at Institute of Microbiology, Chinese Academy of Sciences. He received his doctor's degree from Technical University of Munich (TUM), Germany. His research is mainly focused on the design and development of novel vaccines against major pathogens and the mechanism of protective immune response. Important research and translational achievements have been made in the research and development of vaccines against coronaviruses, Zika virus and other emerging infectious diseases, among which the recombinant protein subunit COVID-19 vaccine has been approved for use in many countries. The results are published as first/corresponding authors in the journals including Cell, The New England Journal of Medicine, Nature Immunology, Nature Reviews Immunology, Cell Host & Microbe. He is supported by the National Science Fund for Excellent Young Scholars, and is the winner of VCANBIO Award for Biosciences and Medicine, excellent member of the Innovation Promotion Association of Chinese Academy of Sciences, and the Young Scholar Award of Chinese Society of Immunology.

Dr. Shen Haifa is co-founder and CTO of StemiRNA Therapeutics. He received his PhD degree from the Graduate School of Biomedical Sciences, the University of Texas/ M D Anderson Cancer Center in 1997, and completed his post-doctoral training at National Cancer Institute in 2001. He then joined the biopharmaceutical industry and worked there for eight years on cancer drug discovery and development. He went back to academia afterwards, focusing his research on drug design and drug delivery platforms. Dr. Shen was professor at Houston Methodist Hospital and founding director of the Innovative Therapeutics program at Houston Methodist Cancer Center, Weill Cornell Medical College of Cornell University. Dr. Shen and his group have published more than 110 peer-reviewed research articles including those in Nature, Nature Biotechnology, and Science Immunology, and have over 10 patents and patent applications.

Xiangrong Song is a full professor at Sichuan University and a pharmaceutical scientist at National Key Laboratory of Biotherapy. The Song lab has developed the targeted delivery systems for gene drugs and small molecules to treat tumors, atherosclerosis, ocular diseases, infection or brain diseases. Two novel drug candidates (IND) have been approved for phase I clinical trials. She has authored more than 100 papers and is an inventor of more than 50 issued / pending patents worldwide. The technologies that Dr. Song and her colleagues have developed formed the basis for the launch of 2 biotechnology companies. The two companies are translating the aforementioned academic innovations toward commercialization and societal impact. In 2019, she was a recipient of the first prize of Science and Technology Award in Chinese National Medicine Association, for the research on immune function of Yi nationality's medicine. In 2022, she was named as the elite of science and technology in China.

Kiat Ruxrungtham, is a Professor of Medicine, Department of Medicine , Faculty of Medicine, Chulalongkorn University; and Scientific Chair of the Chula Vaccine Research Center (ChulaVRC); and Director of the Covid19 Vaccine Development Program, ChulaVRC. He is providing teaching and patient care on Allergy -Clinical Immunology and HIV Medicine at the King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University; and is mentoring junior researchers on HIV medicine at HIVNAT, TRCARC; vaccine and Immunology (at Chula Vaccine Research Center); and also on clinical trials. He is currently leading the Chula-Covid19 mRNA vaccine development program at ChulaVRC. Honors: He has received several awards: 2006 Outstanding Internist Award on Medical Academy, Royal College of Physicians, Thailand 2007 Outstanding Researcher Award, and the Highest Citation Award, Chulalongkorn University, Bangkok, Thailand 2011 Senior Research Scholar Award, the Thailand Research Fund 2011 Outstanding Researcher Award, National Research Council, Thailand 2015 Senior Research Scholar Award, the Thailand Research Fund 2015 Outstanding Research Award, the Thailand Research Fund 2022 A Royal Award “Contributors to the development of the country’s vaccines” from Her Royal Highness Princess Maha Chakri Sirindhorn at the 10th Vaccination Conference Publications: He has published more than 370 peer review papers on HIV, immunology, allergy, and vaccine. Contributions to national and international academics and professional organization: 1. Former President of the Allergy, Asthma and Immunology Association, Thailand (AAIAT) 2. Former President of the Thai AIDS Society (TAS) 3. Co-chair of the Co-chair of the APAACI and APAAAPARI 2018, Bangkok, Thailand 4. Co-chair of the World Allergy Congress 2023, Bangkok, Thailand 5. Chief-editor, Asian Pacific Journal of Allergy and Immunology (APJAI)

Dr. Jeff Zhu is the founder and CEO of Shanghai Reinovax Biologics co., Ltd., a fast-growing biotech company focusing on discovery and development of innovative vaccines and other biologics. Dr. Zhu has over 20 years’ industrial experience on discovery and development of small molecules, recombinant proteins, antibodies and vaccines from the early discovery to clinical trials. He played an important role in moving multiple drug candidates from the initiation to the clinical trial stage during his 13-year tenure at Pfizer’s R & D center in San Diego. Dr. Zhu moved back to China in 2011, and served as CSO and head of the R & D at Hualan Biological Engineering Inc., and two years later worked as senior director and department head in USP, Shanghai. Dr. Zhu published earned his Ph.D. degree on biological sciences from UC, Irvine, M.S. degree on biochemistry from Georgetown university, and B.S. degree on chemistry from Tsinghua university.

Yongming Chen received his Ph.D. on polymer science in 1993 from Nankai University. From 1994 to 1998, he was Postdoctoral Researcher and later Research Assistant at the Institute of Chemistry, CAS. Then he spent the period 1998−2001 as Postdoctoral Researcher in University of Düsseldorf and University of Mainz. Since 2001, Chen was Professor at the Institute of Chemistry CAS. He moved to Sun Yat-sen University in 2013. He obtained “Distinguished Young Scholars” by National Science Foundation of China (2006). He served for Polymer, an Elsevier journal, as an Associate Editor during 2007 to 2018. He also was in Advisory Board Panel of Macromolecules and ACS Macro Letters, the ACS Publication. Professor Chen’s research interests are in the areas of biomaterials chemistry and biomaterials application in delivery of proteins and nucleic acids, specifically application in immune attenuation. He has published over 260 research articles in Science Advances, Nature Communication, Biomaterials, Nano Letters et al and obtained 10 more licenced patents.

Dr. Alex Li is the COO and Head of research for Axter Therapeutics Inc. Since its establishment at the end of 2021, the Axter mRNA platform has developed a number of highly efficient LNP delivery systems with independent intellectual property rights, including immune system-targeted LNP for preclinical research of mRNA tumor vaccines and antiviral vaccines. Dr. Alex Li is a Board Director of the Sino-American Pharmaceutical Professional Association (SAPA), former President of SAPA-NE, and Visiting Professor of the Chinese Academy of Medical Sciences (Peking Union Medical College). He worked in Biogen for 17 years (2000-2017), participating in the research and development of 6 new approved drugs, including the evaluation, licensing-in and lead research of the first successful anti-sense oligo drug Spinraza for Biogen. Prior to joining Axter, Dr. Li received his MBA and Ph.D. in molecular biology from the University of Tennessee, Knoxville.

Tianping WANG, graduated from Renmin University of China with a master's degree, Director of International Regulatory Affairs, Group Quality Department Manager of Sinovac Biotech Ltd. Leading person in passing WHO PQ/EUL for four vaccines and obtaining nearly 300 international regulatory approvals in more than 40 countries for multiple vaccines. Coauthor of WHO Vaccine Prequalification Guidance. Responsible for promoting key projects such as COVID-19 overseas clinical trials and technical licensing, and participating in drawing the blueprint of international development strategy for Sinovac.

Dr. Sun, CEO & President of AbMax Biotechnology, Inc., Thousand Talent of Beijing, Adjunct Prof. of Beijing Normal University. He received his PhD in biochemistry from Tsinghua Univ. in 1989 and finished his postdoctoral study in Dr. David Barnes’s lab at Oregon State Univ. He has more than 30 yrs experience in antibody-based research and drug development. He was Director of R& D at Upstate Biotechnology Inc., a market leader in the research reagent sector. In 2000, as co-founder and the President, he started A&G Pharmaceutical in Baltimore, created the record of “Generation of mAb in 28 days” and received $2.5 M investment from MedImmune in 2001. In 2004, he started Welson Pharmaceuticals working on antibody drug conjugate, now has one leading candidate in co-development with a Chinese Pharma. In 2006, he started AbMax as a Biotech CRO, established the largest collection of mAbs against infectious diseases. Using AbEpiMax, the ONLY B cell-epitope identification program, and AbADCCZero, IP-protected De-ADCC technology, his team is developing 15+ Bio-Betters of Block-burst antibody drugs for I/O and auot-immune diseases. He has published 40+ papers on journals such as Nature Med., Nature Genetics, Immunity, Development Cell, etc.

Dr. Qiu is the General Manager of Vaccine Clinical Center of CSPC Group. He joined the vaccine industry in 2005 and has been engaged in vaccine early stage R&D, clinical research and medical affairs for nearly 18 years. He has served in Beijing Institute of Biological Products, Sinovac Biotech, GlaxoSmithKline, Sanofi Pasteur, Merck Sharp & Dohme and Fosun Pharmaceuticals, where he was responsible for the early development of pneumococcal conjugate vaccine and Hib vaccine, and registration clinical trials with human avian influenza vaccine (H5N1), influenza A/H1N1 vaccine, DTaP-based combined vaccines, meningococcal conjugate vaccine, MMR varicella combined vaccine, polio inactivated vaccine, rotavirus vaccine, HPV vaccine, and SARS-CoV-2 mRNA vaccine. He was also responsible for the post-marketing clinical research and medical support for various vaccines. He is now working for CSPC Group and is responsible for the clinical studies of the vaccine product line.

Nektaria Karavas is the Global Director of Business Development for Nasal Vaccines, Antivirals and Immuno-stimulants at Aptar Pharma. Ms. Karavas joined Aptar Pharma in 2004 and has held various commercial roles executing long-term strategy within key customer and global accounts in North America focusing on nasal drug delivery. She has contributed to multiple nasal development programs, supported commercial scale up and product launches for New Drug Applications (NDA) using an Aptar delivery device for key pharmaceutical clients across different therapeutic indications. Nektaria holds a Bachelor of Science from McGill University, Montreal, Canada

Dr. Julie D. Suman is the Vice President of Scientific Affairs for Aptar Pharma. She manages strategic scientific planning and Aptar’s Scientific Advisory Board. Dr. Suman is also the co-founder of Next Breath. She holds a B.S. in Pharmacy from Duquesne University (1996) and a Ph.D. in Pharmaceutical Sciences from the University of Maryland, Baltimore (2002). Dr. Suman serves on the External Advisory Committee of the New South Wales RNA Production and Research Network. In addition, she is a co-editor for Respiratory Drug Delivery Proceedings, an international symposium, and an an Affiliate Assistant Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Dr. Suman is the Past-Chair of the AAPS Inhalation Technology Focus Group. Dr. Suman is also a member of the Parental Drug Association Visible Particulate Taskforce. She is a licensed Maryland pharmacist. Dr. Suman has published her research in peer-reviewed journals and has been presented during podium sessions at international meetings, the FDA Topics in Bioequivalence Seminar Series and has been an invited speaker at ANVISA in Brazil. Dr. Suman’s doctoral research, which focused on the relationship between in vitro tests for nasal sprays and in vivo deposition, has been recognized for excellence by a research award presented at the International Society for Aerosols in Medicine, 2001. In 2008, Dr. Suman received an award from the Greater Baltimore Committee for Entrepreneurial Spirit.

Dr. Alex Li is the COO and Head of research for Axter Therapeutics Inc. Since its establishment at the end of 2021, the Axter mRNA platform has developed a number of highly efficient LNP delivery systems with independent intellectual property rights, including immune system-targeted LNP for preclinical research of mRNA tumor vaccines and antiviral vaccines. Dr. Alex Li is a Board Director of the Sino-American Pharmaceutical Professional Association (SAPA), former President of SAPA-NE, and Visiting Professor of the Chinese Academy of Medical Sciences (Peking Union Medical College). He worked in Biogen for 17 years (2000-2017), participating in the research and development of 6 new approved drugs, including the evaluation, licensing-in and lead research of the first successful anti-sense oligo drug Spinraza for Biogen. Prior to joining Axter, Dr. Li received his MBA and Ph.D. in molecular biology from the University of Tennessee, Knoxville.

Dr. Tan is responsible for drug discovery, preclinical development, translation research and external collaboration in China. Dr. Tan got his Ph.D. in Molecular Medicine from UT Health Science Center San Antonio and received his Postdoctoral training with Dr. Michael Karin at UC San Diego. Dr. Tan worked in Pfizer and Novartis for 9 years, specialized in drug discovery and translational research, bridging preclinical research to early clinical trials. Dr. Tan worked at Biosion Biotech and Coherent Biopharma before he joined Clover. Dr. Tan was selected as Jiangsu Innovation and Entrepreneur Talent and Suzhou Innovation and Entrepreneur Leading Talent.